BACKGROUND: The need for formal and structured approaches for benefit-risk assessment of medicines is increasing, as is the complexity of the scientific questions addressed before making decisions on the benefit-risk balance of medicines. We systematically collected, appraised and classified available benefit-risk methodologies to facilitate and inform their future use. METHODS: A systematic review of publications identified benefit-risk assessment methodologies. Methodologies were appraised on their fundamental principles, features, graphical representations, assessability and accessibility. We created a taxonomy of methodologies to facilitate understanding and choice. RESULTS: We identified 49 methodologies, critically appraised and class...
AbstractBackgroundPatients, physicians, and other decision makers make implicit but inevitable trade...
Pharmaceutical drugs and devices are increasingly evaluated by quantitative tools that combine benef...
Currently, regulators make marketing authorisation decisions based on the benefit-risk balance of a ...
BACKGROUND: The need for formal and structured approaches for benefit-risk assessment of medicines i...
Benefit–risk assessment in medicine has been a valuable tool in the regulation of medicines since th...
Purpose One of the most important uses of benefit-risk assessment pertains to approval of new medic...
In order for a medicinal product to get marketing authorization in Europe, it has to demonstrate a p...
Over the past 5 years, the environment for developing new medicines has become increasingly “risk av...
Assessing the utility of structured approaches to benefit-risk assessment of medicinal products is c...
Purpose Decisions leading to drug approval demand careful attention with respect to balancing benefi...
PURPOSE: Difficulties may be encountered when undertaking a benefit-risk assessment for an older pro...
Purpose Optimizing a therapeutic product's benefit-risk profile is an on-going process throughout th...
Purpose Optimizing a therapeutic product's benefit-risk profile is an on-going process throughout th...
Background: The main responsibility of regulators and industry is to ensure the benefit-risk balance...
Joint evaluation of drugs’ beneficial and adverse effects is required in many situations, in particu...
AbstractBackgroundPatients, physicians, and other decision makers make implicit but inevitable trade...
Pharmaceutical drugs and devices are increasingly evaluated by quantitative tools that combine benef...
Currently, regulators make marketing authorisation decisions based on the benefit-risk balance of a ...
BACKGROUND: The need for formal and structured approaches for benefit-risk assessment of medicines i...
Benefit–risk assessment in medicine has been a valuable tool in the regulation of medicines since th...
Purpose One of the most important uses of benefit-risk assessment pertains to approval of new medic...
In order for a medicinal product to get marketing authorization in Europe, it has to demonstrate a p...
Over the past 5 years, the environment for developing new medicines has become increasingly “risk av...
Assessing the utility of structured approaches to benefit-risk assessment of medicinal products is c...
Purpose Decisions leading to drug approval demand careful attention with respect to balancing benefi...
PURPOSE: Difficulties may be encountered when undertaking a benefit-risk assessment for an older pro...
Purpose Optimizing a therapeutic product's benefit-risk profile is an on-going process throughout th...
Purpose Optimizing a therapeutic product's benefit-risk profile is an on-going process throughout th...
Background: The main responsibility of regulators and industry is to ensure the benefit-risk balance...
Joint evaluation of drugs’ beneficial and adverse effects is required in many situations, in particu...
AbstractBackgroundPatients, physicians, and other decision makers make implicit but inevitable trade...
Pharmaceutical drugs and devices are increasingly evaluated by quantitative tools that combine benef...
Currently, regulators make marketing authorisation decisions based on the benefit-risk balance of a ...